Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of dacarbazine in MGMT-expressing metastatic colorectal carcinoma
2011-002080-21Phase 2Completed
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacarbazine in colorectal cancer (CRC), sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Objective response rate by RECIST. Started Feb 2012; status: completed.
02
Drugs
dacarbazine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-002080-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002080-21.